Clinicians can use new monoclonal antibody therapies to treat high-risk patients presenting with mild to moderate COVID-19 symptoms. However, despite the promise to depress viral loads, logistical and other challenges continue to stand in the way of larger-scale use. Still, some EDs are trying the therapeutics, with promising results.